On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- No Impact of Transport Seen on Comirnaty’s mRNA Content or Expression of Spike Proteins: NIHS Study
May 10, 2021
- New Industry Vision to Reaffirm Pharmaceuticals as Growth Industry: MHLW Director
April 30, 2021
- MHLW to Set New Generic Target of 80% in Every Prefecture by FY2023-End
April 30, 2021
- LDP’s Project Team Calls for Audacious Gov’t Investment Targets for Drug Discovery Capabilities
April 30, 2021
- MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
April 30, 2021
- Bayer’s Heart Failure Med Now in Line for June Approval
April 30, 2021
- Large-Scale Vaccination Center to Open in Tokyo on May 24
April 28, 2021
- LDP Project Team Submits Proposal, Minister Vows to Subsidize Morning/Nighttime Vaccinations
April 28, 2021
- Rebuild Vaccine Development System as National Security: CEFP Members
April 27, 2021
- LDP Team Adopts Proposals to Push Japan-Made COVID-19 Vaccines, Urges Approval with Safety/Immunogenicity Studies
April 27, 2021
- Japan Eyes Different Supply Routes for Non-Pfizer COVID-19 Vaccines: Kono
April 26, 2021
- Don’t Take Vaccines If You Feel Ill: Safety Panels to Elderly
April 26, 2021
- Japan PM Mulls Legal Revision on Trial Requirement for Vaccines
April 26, 2021
- Olumiant Snags Japan Approval for COVID-19
April 23, 2021
- MSD’s Recarbrio, Rinvoq’s Psoriasis Use Clears PAFSC Review; June Approval Likely
April 22, 2021
- Major Modifications of CEA Scheme Difficult with Few Examples: Chuikyo
April 22, 2021
- Chuikyo Reps Warn Each Other over 2% Adjustment Rate in Drug Price Revisions
April 22, 2021
- MSD Developing 2-Dose Regimen for 9-Valent HPV Vaccine: Panel
April 22, 2021
- Olumiant Now in Line for Japan Nod for COVID-19 Pneumonia
April 22, 2021
- Vaccine Industry Group Calls for Govt’s Control Functions for Infectious Diseases
April 21, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…